HOME >> BIOLOGY >> NEWS
Potent possibilities for parasite attack

A comparison of three parasite species that cause Leishmaniasis has identified a small number of genes, many new to biology, that will provide a framework to target the search for new treatments. Leishmaniasis is a devastating disease that affects about two million people each year and threatens one-fifth of the world's population and new treatments are desperately needed.

In their report in Nature Genetics, published online on Sunday 17 June 2007, the researchers compared the genomes of L. infantum and L. braziliensis, which cause life-threatening visceral and disfiguring mucocutaneous leishmaniasis, respectively, with the sequence they produced in 2005 for L. major, which causes a less severe, cutaneous form of the disease. Despite the major differences in disease type, only 200 out of more than 8000 genes present in each genome were found to be differentially distributed between the three species. This exceptionally small variation in gene content has given new insights into those processes that may determine disease severity in humans.

"Identifying factors that allow three closely related organisms to cause vastly different clinical outcomes is a major quest for researchers and in this study we have narrowed the search to a number that can be realistically studied," commented Dr Matt Berriman, senior author on the paper, from the Wellcome Trust Sanger Institute.

The researchers found only five genes in the L. major genome for which no trace could be found in the other two species. By contrast, in Plasmodium, which causes malaria, about 20% of genes differ between related species.

"Clearly there must have been considerable evolutionary pressure over time to maintain the structure and sequence of the Leishmania genomes - the degree of similarity between these species was unexpected," explained Professor Deborah Smith, collaborator on this project at the University of York. "Perhaps only a few parasite genes are importan
'"/>

Contact: Don Powell
don@sanger.ac.uk
44-012-234-94956
Wellcome Trust Sanger Institute
17-Jun-2007


Page: 1 2 3

Related biology news :

1. Potential genetic testing for substance abuse raises hope, concern
2. Potential for malaria transmission higher than previously thought
3. Potential new therapeutic target for asthma, allergies and cancer
4. Potential diagnostic marker indicates effectiveness of anti-angiogenic drugs
5. Potential new treatment strategy for Alzheimers disease and other brain and spinal cord damage
6. Potential vaccine developed for deadly leishmaniasis disease
7. LIAI initiatives battle influenza; Potential bird flu treatment among their findings
8. Potential malaria drug target identified
9. Potentially harmful fluoride levels found in some instant teas
10. Potent anticancer drug increases function of axons in mouse model of neurodegeneration
11. Potential new oncogene may be missing link in cancer-causing chain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... ... today announced that it has entered into a multi-year contract with Merus ... support their translational and clinical research strategy to discover and develop ground-breaking ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, ... a UK supplier and manufacturer of innovative portable renewable energy equipment, have announced ... fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... available for free its new white paper – Simulated Transport Methodologies. Regulatory ... today’s biologics licensing application (BLA). In response, Modality Solutions shares an explanation ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health ... growth, , Known as MediVet Biologics since its formation in ... The new Ardent Animal Health will build on its base of innovative therapies ...
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
Breaking Biology Technology:
Cached News: